Second primary malignancies among women with uterine sarcoma
Por:
Koivisto-Korander, R, Scelo, G, Ferro, G, Mellemkjaer, L, Hemminki, K, Weiderpass, E, Tamaro, S, Pompe-Kirn, V, Tracey, E, Brewster, D, Kliewer, E, Tonita, J, Kee-Seng, C, Jonasson, J, Martos, C, Brennan, P, Straif, K and Pukkala, E
Publicada:
1 jul 2012
Resumen:
Objective. Uterine sarcomas (US) are rare malignancies with unclear aetiology. Studies on uterine sarcomas in the setting of second primary malignant tumours can provide clues to aetiology and identify side effects of different treatments.
Methods. A cohort of 8606 cases of US was extracted from the data from 13 cancer registries and followed for second primary cancers within the period 1943-2000. Standardized incidence ratios (SIRs) were calculated, and Poisson regression analyses were performed.
Results. There were 499 cancer cases observed after a first diagnosis of US (SIR 1.26, 95%CI 1.16-1.38). SIRs were elevated for cancers of the mouth and pharynx (2.16, 95%CI 1.15-3.69), colorectum (1.60, 95%CI 1.28-1.98), lung (1.73, 95%CI 1.27-2.29), breast (1.25, 95%CI 1.05-1.49), urinary bladder (1.74, 95%CI 1.02-2.79), kidney (2.00, 95%CI 1.24-3.06), thyroid gland (2.74, 95%CI 1.42-4.79), and soft tissue sarcoma (5.23, 95%CI 2.51-9.62). The risk of breast cancer increased along with increasing age of US diagnosis (p trend 0.040). The risk of kidney cancer increased along with decreasing age of US diagnosis (p trend 0.004) and short time since the US diagnosis (p trend 0.018).
Conclusions. Our study demonstrated increased risk of certain cancers following a diagnosis of US. The elevated risk for breast cancer may indicate shared hormonal aetiology, while the increased risk of colorectal and bladder cancers after US may be caused by radiation therapy of US. The clustering of smoking-related cancers after US is worth exploring in the future. (c) 2012 Elsevier Inc. All rights reserved.
Filiaciones:
Koivisto-Korander, R:
Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland
Scelo, G:
IARC, Lyon, France
Ferro, G:
IARC, Lyon, France
Mellemkjaer, L:
Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark
Hemminki, K:
German Canc Res Ctr, Div Mol Genet Epidemiol, Heidelberg, Germany
Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
Weiderpass, E:
Canc Registry Norway, Oslo, Norway
Dept Community Med, Tromso, Norway
Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
Samfundet Folkhalsan, Helsinki, Finland
Tamaro, S:
British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
Pompe-Kirn, V:
Canc Registry Slovenia, Inst Oncol, Ljubljana, Slovenia
Tracey, E:
New S Wales Canc Registry, Eveleigh, NSW, Australia
Brewster, D:
NHS Natl Serv Scotland, Informat Serv Div, Scottish Canc Registry, Edinburgh, Midlothian, Scotland
Kliewer, E:
British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
CancerCare Manitoba, Epidemiol & Canc Registry, Winnipeg, MB, Canada
Univ Manitoba, Winnipeg, MB, Canada
Tonita, J:
Saskatchewan Canc Agcy, Regina, SK, Canada
Kee-Seng, C:
Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore
Singapore Canc Registry, Singapore, Singapore
Jonasson, J:
Iceland Canc Soc, Iceland Canc Registry, Reykjavik, Iceland
Univ Iceland, Fac Med, Reykjavik, Iceland
:
Canc Registry Zaragoza, Hlth Dept Aragon Govt, Zaragoza, Spain
Brennan, P:
IARC, Lyon, France
Straif, K:
IARC, Lyon, France
Pukkala, E:
Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland
Finnish Canc Registry, Inst Stat & Epidemiol Canc Res, FIN-00170 Helsinki, Finland
|